EVMS Scientist Named Virginia Outstanding Scientist for 2016
Saturday, March 19, 2016
Dr. Jerry Nadler, Internal Medicine Chairman & Vice Dean of Research at Eastern Virginia Medical School, who is making potentially game-changing advances in diabetes research, has been named Virginia’s Outstanding Scientist for 2016.
Governor Terry McAuliffe presented the award during a ceremony in Richmond. The prestigious recognition is part of the annual Virginia's Outstanding STEM Awards, given by the Science Museum of Virginia. Dr. Nadler is one of two to receive this year's Outstanding Scientist award.
"Dr. Nadler is not only a first-class researcher, educator and clinician, he also recruits wonderful people and he's able to mentor great researchers and clinical scientists like himself,” says Richard Homan, MD, President and Provost and Dean of the School of Medicine. “He's a resource not only for EVMS but for the commonwealth of Virginia, the nation and for medicine."
Jerry Pepe, PhD, Professor and Chair of Physiological Sciences and former EVMS Dean, says Dr. Nadler has elevated the school’s research reputation and brought advanced diabetes care to the region and the state. “There's nobody who has done more for diabetes research and diabetes care over the past 10 years than Jerry Nadler,” he says.
Dr. Nadler is Vice Dean for Research, the Harry H. Mansbach Chair in Internal Medicine and Chair of Internal Medicine. He leads a team of researchers whose discoveries may lead to new treatments for the nearly 400 million people worldwide with diabetes and countless others who are pre-diabetic.
Peers around the globe have taken note of Dr. Nadler’s research that shows diabetes is an inflammatory disease. He has identified new targets for therapy, a process that has led to more than 10 patents. His research could lead to new treatments to prevent or possibly even reverse type 1 diabetes, a form of the disease that typically strikes in childhood.
His research has focused on the role of lipid and immune inflammatory pathways leading to pancreatic beta cell damage and better understanding of the cardiovascular complications of diabetes. He is also working to identify new biomarkers for development of type 1 diabetes and ways to prevent disease development.